The Impact of Mitochondrial Dysfunction in Amyotrophic Lateral Sclerosis

Cells. 2022 Jun 28;11(13):2049. doi: 10.3390/cells11132049.

Abstract

Amyotrophic lateral sclerosis (ALS) is a rapidly progressive and highly fatal neurodegenerative disease. Although the pathogenesis of ALS remains unclear, increasing evidence suggests that a key contributing factor is mitochondrial dysfunction. Mitochondria are organelles in eukaryotic cells responsible for bioenergy production, cellular metabolism, signal transduction, calcium homeostasis, and immune responses and the stability of their function plays a crucial role in neurons. A single disorder or defect in mitochondrial function can lead to pathological changes in cells, such as an impaired calcium buffer period, excessive generation of free radicals, increased mitochondrial membrane permeability, and oxidative stress (OS). Recent research has also shown that these mitochondrial dysfunctions are also associated with pathological changes in ALS and are believed to be commonly involved in the pathogenesis of the disease. This article reviews the latest research on mitochondrial dysfunction and its impact on the progression of ALS, with specific attention to the potential of novel therapeutic strategies targeting mitochondrial dysfunction.

Keywords: amyotrophic lateral sclerosis; mitochondrial dysfunction; neurodegenerative diseases.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amyotrophic Lateral Sclerosis* / metabolism
  • Calcium / metabolism
  • Humans
  • Mitochondria / metabolism
  • Neurodegenerative Diseases* / metabolism
  • Oxidative Stress / physiology

Substances

  • Calcium

Grants and funding

This study was supported by the Shandong Province Natural Science Foundation of China (Grant No. ZR2020MH150, ZR2020MH149, and ZR2019BH060), Support Program for Youth Innovation Technology in Colleges and Universities of Shandong Province of China (Grant No. 2019KJK004), Key Project of Shandong Province Higher Educational Science and Technology Program of China (Grant No. J18KZ013), Shandong Medical and Health Science and Technology Development Plan Project (Grant No. 2019WS606) and Grants from the Brigham and Women’s Hospital BRI Fund to Sustain Research Excellence (to X.W.), Gillian Reny Stepping Strong Center for Trauma Innovation, Osteobiology Research Fund, and Osteobiology Training Fund (to S.Z.).